ArticleInflammatory bowel diseases2019
Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort.
Article in Inflammatory bowel diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06864403 (Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch), which is not on this map. Cited by 51 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
Who cites it
51 citing papers in PubMed, 4 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- PAVFCOS: The development of a core outcome set for pouch anal and vaginal fistula.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2025Pooled it
- Medical Therapies for Prevention and Treatment of Inflammatory Pouch Disorders-A Systematic Review and Meta-Analysis.The American journal of gastroenterology · 2025Pooled it
- AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders.Gastroenterology · 2024Guideline
- Is Ustekinumab Effective in Refractory Crohn's Disease of the Pouch and Chronic Pouchitis? A Systematic Review.Digestive diseases and sciences · 2022Pooled it
- Review
- Comparative Effectiveness of Biologic Therapies in Chronic Pouchitis and Crohn's-Like Disease of the Pouch: A Bi-center Retrospective Cohort Study.Digestive diseases and sciences · 2026Article
- Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCU.Therapeutic advances in gastroenterology · 2026Article
- Efficacy and Safety of Ustekinumab and Vedolizumab for Crohn's Disease of the Pouch.Inflammatory bowel diseases · 2025Article
- Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis.Digestive diseases and sciences · 2025Article
- Integrins and pulmonary fibrosis: Pathogenic roles and therapeutic opportunities.Biomolecules & biomedicine · 2025Review
- Managing Pouchitis: Where do Antibiotics End, and Advanced Therapies Begin?Current gastroenterology reports · 2025Review
- Incidence, Risk Factors, and Outcomes of Chronic Antibiotic-Refractory Pouchitis in Korean Patients with Ulcerative Colitis.Gut and liver · 2025Article
- Medical, Endoscopic, and Surgical Treatments for Rectal Cuffitis in IBD Patients with an Ileal Pouch-Anal Anastomosis: A Narrative Review.Digestive diseases and sciences · 2025Review
- Crohn's-like Ileal Pouch Illness and Ileal Pouch Salvage Strategies.Clinics in colon and rectal surgery · 2025Review
- Endoscopic Normalization and Transition of J-Pouch Phenotypes Over Time in Patients With Inflammatory Bowel Disease.Inflammatory bowel diseases · 2025Article
- Pouchitis unveiled: exploring clinical features, diagnosis, and cutting-edge treatments.Therapeutic advances in gastroenterology · 2025Review
- Real-world effectiveness of vedolizumab in refractory pouchitis: a focus on biomarker changes during intravenous to subcutaneous transition (POUCHIVED study).Frontiers in immunology · 2025Observational
- Impact of Obesity on the Long-Term Outcomes of Advanced Therapies in IBD: A Real-World Study in Taiwan.Journal of inflammation research · 2025Article
- Approach to Therapy for Chronic Pouchitis.Annual review of medicine · 2025Review
- Key Focus Areas in Pouchitis Therapeutic Status: A Narrative Review.Iranian journal of medical sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsInflammation of the pouch after ileal pouch-anal anastomosis (IPAA) can significantly impact quality of life and be difficult to treat. We assessed the effectiveness and safety of vedolizumab in Crohn's disease (CD) of the pouch and chronic antibiotic-dependent or antibiotic-refractory pouchitis.
methodsThis was a retrospective, multicenter cohort study at 5 academic referral centers in the United States. Adult patients with endoscopic inflammation of the pouch who received vedolizumab were included. The primary outcome was clinical response at any time point. Secondary outcomes included clinical remission, endoscopic response, and remission. Univariate analysis and multivariate analysis were performed for the effect of the following variables on clinical response: fistula, onset of pouchitis less than 1 year after IPAA, younger than 35 years old, gender, previous tumor necrosis factor inhibitor-alpha use, and BMI >30.
resultsEighty-three patients were treated with vedolizumab for inflammation of the pouch between January 2014 and October 2017. Median follow-up was 1.3 years (interquartile range 0.7-2.1). The proportion of patients that achieved at least a clinical response was 71.1%, with 19.3% achieving clinical remission. Of the 74 patients with a follow-up pouchoscopy, the proportion of patients with endoscopic response and mucosal healing was 54.1% and 17.6%, respectively. Patients who developed pouchitis symptoms less than 1 year after undergoing IPAA were less likely to respond to vedolizumab, even after controlling for other risk factors.
conclusionsVedolizumab is safe and effective in the management of CD of the pouch and chronic pouchitis. Further studies are needed to compare vedolizumab with other biologic therapies for pouchitis and CD of the pouch.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.